CG Oncology: Full Cohort CX data reinforces creto as long-term factor across NMIBC

Research evidence excerpt

CG Oncology: Full Cohort CX data reinforces creto as long-term factor across NMIBC

Accessible version

CG Oncology

Full Cohort CX data reinforces creto as

long-term factor across NMIBC

Maintain Rating: BUY | PO: 87.00 USD | Price: 66.93 USD

Combination looks feasible in BCG-exposed, -UR settings 18 May 2026

We view the CORE-008 Cohort CX update at AUA as reinforcing the potential for Equity

cretostimogene to serve as a bladder-sparing backbone across the broader HR NMIBC

Alec W. Stranahan

landscape beyond the initial BCG-unresponsive (BCG-UR) monotherapy opportunity. Research Analyst

While we expect investors will need to see durability data to determine whether the BofAS +1 646 743 2109

combination meaningfully improves vs. monotherapy (median follow-up remains early at alec.stranahan@bofa.com

6.6 months), the key takeaway, in our view, is that the creto + gemcitabine combination Matthew Guggenbiller

generated strong early activity while preserving the intravesical-only profile that should Research Analyst BofAS

be familiar to urologists and scalable in community practice, where >80% of patients in +1 646 855 5170

the study were treated. We also note the trials-in-progress poster for the FDA-aligned matthew.guggenbiller@bofa.com

SWOG S2611 phase 3 study of creto + gem vs. gem/doce in HR BCG-UR NMIBC – we

think this trial (powered to detect an improvement in 2-yr EFS from 40% with gem/doce

to 55% with creto + gem with a hazard ratio of 0.65) could impact how creto is used Stock Data

commercially, assuming BLA approval. We maintain Buy and $87 PO.

Price 66.93 USD

Early efficacy points to promise vs. creto mono, TAR-200 Price Objective 87.00 USD

Date Established 15-May-2026

Early efficacy signals were encouraging, with overall HG-EFS of 96.0% at 3 months and